Skip to main content
Top

12-09-2017 | Kaposi sarcoma | Article

The pattern of secondary cancers in patients with Kaposi sarcoma in the United States

Journal: Cancer Causes & Control

Authors: Vivek Kumar, Mohit Garg, Neha Chaudhary, Parita Soni, Charalampos S. Floudas, Chiemeziem Nwanyanwu, Abhinav Chandra

Publisher: Springer International Publishing

Abstract

Purpose

In the U.S., Kaposi sarcoma (KS) occurs mostly in HIV-infected patients, who are also at increased risk of developing secondary cancers. The trends in secondary cancer risk are unclear in the HAART era.

Methods

We extracted data from the SEER database on patients diagnosed with KS between 1981 and 2013, stratified into the pre-HAART (1981–1995) and HAART (1996–2013) eras. We compared the risk of secondary cancer in KS patients and the general population, and estimated the absolute risk.

Results

We followed 13,535 KS patients for 49,813 person-years, during which 1,041 secondary cancers were diagnosed: 774 in the pre-HAART and 267 in the HAART era. In the pre-HAART era, non-Hodgkin’s lymphoma (NHL) and anal carcinomas were the most common secondary cancers. The standard incidence ratio of secondary cancers decreased from 3.44 (pre-HAART era) to 1.94 (HAART era) in patients aged <70 years. The absolute excess risk decreased from 178 to 68 cases per 10,000 person-years. The risk of NHL decreased, while the risk of anal carcinoma did not change significantly. The risk of lung cancer was lower in KS patients than in the general population. The absolute risk of non-AIDS-defining cancers increased fourfold in the HAART era.

Conclusions

The absolute risk of non-AIDS-defining secondary cancers has increased in KS patients in the HAART era. However, the overall relative risk of secondary cancers has decreased, mainly due to a significant decrease in the risk of NHL.
Literature
1.
Antman K, Chang Y (2000) Kaposi’s sarcoma. N Engl J Med 342(14):1027–1038CrossRefPubMed
2.
Hiatt KM, Nelson AM, Lichy JH et al (2008) Classic Kaposi sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi sarcoma patients with comparison to HIV-related Kaposi sarcoma. Mod Pathol 21(5):572–582CrossRefPubMed
3.
Biggar RJ, Curtis RE, Cote TR et al (1994) Risk of other cancers following Kaposi’s sarcoma: relation to acquired immunodeficiency syndrome. Am J Epidemiol 139(4):362–368CrossRefPubMed
4.
Patel P, Hanson DL, Sullivan PS et al (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148:728–736. doi:10.​7326/​0003-4819-148-10-200805200-00005 CrossRefPubMed
5.
Shiels MS, Pfeiffer RM, Gail MH et al (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):753–762CrossRefPubMedPubMedCentral
6.
Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H (2006) Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 43(2):223–233CrossRefPubMed
7.
Goedert JJ, Vitale F, Lauria C et al (2002) Risk factors for classical Kaposi’s sarcoma. J Natl Cancer Inst 94(22):1712–1718CrossRefPubMed
8.
Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P (2011) Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc 8(3):313–319CrossRefPubMedPubMedCentral
9.
Muggia F (2013) Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated? Oncologist 18(3):245–247. doi:10.​1634/​theoncologist.​2013-0021 CrossRefPubMedPubMedCentral
11.
Delaney M (2006) History of HAART—the true story of how effective multi-drug therapy was developed for treatment of HIV disease. Retrovirology 3(Suppl 1):S6CrossRefPubMedCentral
12.
Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ (2002) Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94(16):1204–1210. doi:10.​1093/​jnci/​94.​16.​1204 CrossRefPubMed
14.
Vishnu P, Aboulafia DM (2012) AIDS-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy. Adv Hematol 2012:485943CrossRefPubMedPubMedCentral
15.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581):59–67CrossRefPubMed
16.
Palefsky JM, Holly EA, Efirdc JT et al (2005) Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 19(13):1407–1414CrossRefPubMed
17.
Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA (2009) Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 101(16):1120–1130CrossRefPubMedPubMedCentral
18.
Righetti E, Ballon G, Ometto L et al (2002) Dynamics of Epstein–Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 16(1):63–73CrossRefPubMed
19.
Cadranel J, Garfield D, Lavolé A, Wislez M, Milleron B, Mayaud C (2006) Lung cancer in HIV infected patients: facts, questions and challenges. Thorax 61(11):1000–1008CrossRefPubMedPubMedCentral
20.
Luu HN, Amirian ES, Scheurer ME (2013) The interaction between smoking status and highly active antiretroviral therapy (HAART) use on the risk of Kaposi’s sarcoma (KS) in a cohort of HIV-infected men. Br J Cancer 108(5):1173–1177CrossRefPubMedPubMedCentral
21.
Anderson LA, Lauria C, Romano N et al (2008) Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily. Cancer Epidemiol Biomark Prev 17(12):3435–3443CrossRef
22.
Hoover DR, Black C, Jacobson LP et al (1993) Epidemiologic analysis of Kaposi’s sarcoma as an early and later AIDS outcome in homosexual men. Am J Epidemiol 138:266–278CrossRefPubMed
23.
Deeken JF, Tjen-A-Looi A, Rudek MA et al (2012) The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 55(9):1228–1235CrossRefPubMedPubMedCentral
24.
Harlan LC, Hankey BF (2003) The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 21(12):2232–2233CrossRefPubMed
25.
Diamond C, Taylor TH, Im T, Wallace M, Saven A, Anton-Culver H (2007) How valid is using cancer registries’ data to identify acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma? Cancer Causes Control 18:135CrossRefPubMed
26.
Engels EA, Pfeiffer RM, Goedert JJ et al (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20(12):1645–1654CrossRefPubMed